scholarly journals Association Between Erectile Dysfunction and Cardiovascular Disease: A Systematic Review

2020 ◽  
Vol 18 (2) ◽  
pp. 59-66
Author(s):  
Sumon Rahman Chowdhury ◽  
Masud Karim ◽  
SM Amanat Ullah ◽  
Muhammed Abu Bakar
Keyword(s):  
Cardiovascular Disease ◽  
Erectile Dysfunction ◽  
Arterial Disease ◽  
Cvd Risk ◽  
Risk Factor Modification ◽  
The Metabolic Syndrome ◽  
Artery Disease ◽  
Peripheral Arterial ◽  
Independent Marker

Erectile Dysfunction (ED) describes the persistent inability to achieve or maintain a penile erection for adequate sexual performance. ED is thought to be a vascular disease affecting more than 70% of men with (Cardiovascular Disease) CVD and sharing a myriad of risk factors like hypertension, smoking, diabetes, obesity, ageing and the metabolic syndrome. Diabetes increases the risk of both ED and CVD with the latter being the leading cause of death. Endothelial dysfunction and its role in the development of atherosclerosis may be the common link between ED, CVD and diabetes. With the current epidemic of type 2 diabetes, diabetes related CVD will increase in tandem. Early identification of this risk group is therefore paramount. Evidence has shown that ED is an independent marker of increased CVD risk and heralds the onset of coronary artery disease, peripheral arterial disease and stroke thereby providing a window of opportunity for risk factor modification. In our paper we shall explore the correlation of ED and CVD with a view to formulation of intervention strategies. Chatt Maa Shi Hosp Med Coll J; Vol.18 (2); July 2019; Page 59-66

193Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
J Udell ◽  
B Zinman ◽  
C Wanner ◽  
M Von Eynatten ◽  
J T George ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Type 2 Diabetes ◽  
Cox Regression ◽  
Arterial Disease ◽  
Outcome Trial ◽  
Artery Disease ◽  
Peripheral Arterial ◽  
Risk And Benefit ◽  
Similar Risk

Abstract Background In type 2 diabetes, the temporal proximity of an atherosclerotic cardiovascular (CV) event can impact prognosis, but whether timing influences sodium glucose co-transporter 2 inhibitor effects is unknown. We explored the association of time from last qualifying CV event before randomisation (myocardial infarction [MI], stroke, coronary artery disease or peripheral arterial disease) with CV outcomes and benefit of empagliflozin (EMPA) in EMPA-REG OUTCOME. Methods Patients (pts) were randomised to EMPA 10 mg, 25 mg or placebo and followed for 3.1 years (median). Risk of major adverse CV events (3P MACE: CV death, MI, stroke), CV death or hospitalisation for heart failure (HHF) were evaluated using Cox regression in subgroups of ≤1/>1 year since last qualifying CV event. Qualifying event stratification was possible in 6796 (97%) pts. Results In the overall population, N=6796 (4547 EMPA and 2249 placebo pts), median (Q1, Q3) time from last CV event was 3.8 (1.5–7.6) years. Overall, 1214 (EMPA 841; placebo 373) and 5582 (EMPA 3706; placebo 1876) pts had a last qualifying CV event ≤1 and >1 year, respectively. Pts with more recent events had similar risk for CV outcomes compared with pts >1 year from qualifying event (Figure). Moreover, the benefit of EMPA on CV outcomes was consistent between pts enrolled ≤1 or >1 year from the qualifying CV event (all p-interaction >0.05; Figure). Conclusion Although most pts had a qualifying CV event >1 year before randomisation in EMPA-REG OUTCOME, the benefits of EMPA appear to extend to pts with more recent CV events. Acknowledgement/Funding Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Plasma copeptin as marker of cardiovascular disease in asymptomatic type 2 diabetes patients

2014 ◽  
Vol 11 (6) ◽  
pp. 448-450 ◽  
Author(s):  
Dana Bar-Shalom ◽  
Mikael K Poulsen ◽  
Lars M Rasmussen ◽  
Axel CP Diederichsen ◽  
Niels PR Sand ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Intima Media Thickness ◽  
Carotid Intima Media Thickness ◽  
Arterial Disease ◽  
University Hospital ◽  
Control Group ◽  
Diabetes Clinic ◽  
Peripheral Arterial

Recently, copeptin was found associated with cardiovascular disease (CVD) and all-cause mortality in type 2 diabetes mellitus (T2DM) patients treated in primary care. This study aimed to evaluate whether plasma copeptin correlated to CVD in asymptomatic T2DM patients intensively investigated for sub-clinical CVD. A total of 302 T2DM patients referred to the Diabetes Clinic at Odense University Hospital, Denmark, entered the study. None of the patients had known or suspected CVD. As a control group, 30 healthy adults were recruited from the DanRisk study – a random sample of middle-aged Danes. A variety of clinical investigations were performed, including blood pressure measurements, carotid intima media thickness evaluation and myocardial perfusion scintigraphy. Blood sample analyses included copeptin measurements. Median plasma copeptin concentrations were similar in the T2DM group and the control group. However, men had significantly higher copeptin concentrations than women in the T2DM group (p < 0.001), and also, T2DM men had significantly higher copeptin concentrations than men without T2DM (p = 0.038). Copeptin correlated significantly with a number of variables, but the strongest correlation was with creatinine (R = 0.432, p < 0.001), and in multiple regression analysis, only this correlation remained significant. When association with clinical scores were investigated, plasma copeptin remained significantly associated with peripheral arterial disease (PAD) (p = 0.01). We found correlations between creatinine, copeptin levels and PAD in T2DM patients, and if confirmed, plasma copeptin combined with plasma creatinine could be a candidate for PAD screening in T2DM patients.

scholarly journals Association of serum Cyr61 levels with peripheral arterial disease in subjects with type 2 diabetes

2020 ◽  
Author(s):  
Feng Bin ◽  
Guidong Xu ◽  
Kangyun Sun ◽  
Kaipeng Duan ◽  
Bimin Shi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Logistic Regression ◽  
Arterial Disease ◽  
Logistic Regression Models ◽  
Patients With Diabetes ◽  
Clinically Significant ◽  
Artery Disease ◽  
Peripheral Arterial ◽  
Fontaine Classification

Abstract Background: The prevalence of peripheral artery disease (PAD) is obviously increased in patients with diabetes. Existing evidence shows that cysteine-rich angiogenic inducer 61 (Cyr61), a 40-kD secreted protein, plays important roles in regulating cellular physiological processes. Recent studies have demonstrated a significant correlation between serum Cyr61 and atherosclerosis. However, the relationship between Cyr61 levels and PAD in patients with type 2 diabetes (T2DM) remains obscure.Methods:. Data from a total of 306 subjects with T2DM were cross-sectionally analysed. The extent of PAD was determined by using the Fontaine classification, which defines four stages. We measured serum Cyr61 concentrations by ELISA in subjects with and without PAD at Fontaine’s stage II, III, or IV. Logistic regression models were used to examine the independent association of Cyr61 with PAD.Results: Out of the 306 subjects enrolled, 150 were free from PAD, while 156 had clinically significant PAD. In subjects with PAD, the prevalences of Fontaine classification stages II, III and IV were 48.7%, 32.1%, and 19.2%, respectively. Patients with more advanced PAD had significantly higher Cyr61 (P for trend < 0.001). The prevalence of PAD on the basis of severity increased with increasing Cyr61 quartiles (all P values for trends < 0.001), and the severity of PAD was positively correlated with Cyr61 quartiles (r = 0.227, P = 0.006). The association of Cyr61 levels with PAD remained after adjusting for major risk factors in a logistic regression analysis.Conclusions: Our results demonstrated that Cyr61 was significantly increased in PAD patients with T2DM and that Cyr61 levels were positively associated with disease severity. Cyr61 could be a promising biomarker and further studies are needed to assess its clinical utility.

scholarly journals Osteoporosis Prevalence and Correlates in Uncomplicated Type 2 Diabetes Mellitus

2021 ◽  
Vol 4 (1) ◽  
pp. 01-06
Author(s):  
Amit Nachankar ◽  
Jitendra Sahu
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Type 2 Diabetes Mellitus ◽  
Arterial Disease ◽  
Increased Risk ◽  
Artery Disease ◽  
Peripheral Arterial ◽  
Osteoporosis Prevalence

Type 2 Diabetes Mellitus (T2DM) is a common metabolic disorder at a pandemic proportion at present. Often T2DM is associated with microvascular (diabetic nephropathy, neuropathy, and retinopathy) and macrovascular complications (coronary artery disease, peripheral arterial disease, and stroke). Additionally diabetic osteopathy is a significant comorbidity of T2DM and is characterized by micro architectural changes that decrease bone quality leading to an increased risk of fragility fracture.

scholarly journals Peripheral Arterial Disease in Type 2 Diabetes Is Associated with an Increase in Fibrinogen Levels

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Qin-Fen Chen ◽  
Dan Cao ◽  
Ting-Ting Ye ◽  
Hui-Hui Deng ◽  
Hong Zhu
Keyword(s):  
Type 2 Diabetes ◽  
Arterial Disease ◽  
Cross Sectional Study ◽  
Fibrinogen Concentration ◽  
Sectional Study ◽  
Cross Sectional ◽  
Noninvasive Measurements ◽  
Artery Disease ◽  
Peripheral Arterial

Background. The present study is undertaken to investigate the fibrinogen levels in type 2 diabetes mellitus (T2DM) and its relation to peripheral artery disease (PAD) based on a more accurate and applied noninvasive measurements of duplex ultrasonography. Methods. We performed a cross-sectional study including 1096 T2DM patients (474 males and 622 females). The odds ratios (ORs) and 95% confidence intervals (CIs) were presented to show the association between PAD and fibrinogen in the subjects divided by fibrinogen levels quarterly. Furthermore, the univariate and multiple logistic analyses were performed to explore the correlation between PAD and fibrinogen levels, individual components in the cross-sectional study. Results. Finally, 887 (80.9%) T2DM patients meet the diagnostic criteria of PAD and these patients had considerably higher serum fibrinogen concentration than non-PAD group (P<0.001). Multiple logistic analyses revealed that higher fibrinogen quartiles were positively related with the development of PAD in the adjusted model. After adjusting for known confounding parameters, the ORs for PAD were 1.993 (95% CI: 1.322-3.005, P<0.001), 2.469 (95% CI: 1.591-3.831, P<0.001), and 2.942 (95% CI, 1.838-4.711, P<0.001) for Q2, Q3, and Q4, respectively (all P values <0.05). Conclusions. Our results suggest that serum fibrinogen concentration can be considered as an independent risk factor for PAD in T2DM patients.

scholarly journals Association of serum Cyr61 levels with peripheral arterial disease in subjects with type 2 diabetes

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Bin Feng ◽  
Guidong Xu ◽  
Kangyun Sun ◽  
Kaipeng Duan ◽  
Bimin Shi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Logistic Regression ◽  
Arterial Disease ◽  
Logistic Regression Models ◽  
Patients With Diabetes ◽  
Clinically Significant ◽  
Artery Disease ◽  
Peripheral Arterial ◽  
Fontaine Classification

Abstract Background The prevalence of peripheral artery disease (PAD) is obviously increased in patients with diabetes. Existing evidence shows that cysteine-rich angiogenic inducer 61 (Cyr61), a 40-kD secreted protein, plays important roles in regulating cellular physiological processes. Recent studies have demonstrated a significant correlation between serum Cyr61 and atherosclerosis. However, the relationship between Cyr61 levels and PAD in patients with type 2 diabetes (T2DM) remains obscure. Methods Data from a total of 306 subjects with T2DM were cross-sectionally analysed. The extent of PAD was determined by using the Fontaine classification, which defines four stages. We measured serum Cyr61 concentrations by ELISA in subjects with and without PAD at Fontaine’s stage II, III, or IV. Logistic regression models were used to examine the independent association of Cyr61 with PAD. Results Out of the 306 subjects enrolled, 150 were free from PAD, while 156 had clinically significant PAD. In subjects with PAD, the prevalences of Fontaine classification stages II, III and IV were 48.7%, 32.1%, and 19.2%, respectively. Patients with more advanced PAD had significantly higher Cyr61 (P for trend < 0.001). The prevalence of PAD on the basis of severity increased with increasing Cyr61 quartiles (all P values for trends < 0.001), and the severity of PAD was positively correlated with Cyr61 quartiles (r = 0.227, P = 0.006). The association of Cyr61 levels with PAD remained after adjusting for major risk factors in a logistic regression analysis. Conclusions Our results demonstrated that Cyr61 was significantly increased in PAD patients with T2DM and that Cyr61 levels were positively associated with disease severity. Cyr61 could be a promising biomarker and further studies are needed to assess its clinical utility.

Sign in / Sign up

Export Citation Format

Share Document